Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
Gut Microbes|November 17, 2022
Nucleotide binding as an allosteric regulatory mechanism for <i>Akkermansia muciniphila</i> β-<i>N</i>-acetylhexosaminidase Am2136Chang-Cheng Li, Huan Yi, Yan-Mei Wang, et al.
Science (New York, N.Y.)|August 3, 2023
Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic targetKai Wang, Zhiwei Zhang, Jing Hang, et al.
Infection and Immunity|January 16, 2019
Structural and Functional Insights into PpgL, a Metal-Independent β-Propeller Gluconolactonase That Contributes to <i>Pseudomonas aeruginosa</i> VirulenceYing-Jie Song, Kai-Lun Wang, Ya-Lin Shen, et al.
Nature Communications|March 19, 2026
Maternal obesity disrupts epigenetic reprogramming via peroxisomal-dependent phospholipid-methyl uncoupling during zygotic genome activationXiao-Guohui Zhang, Lin-Li Yang, Xie Feng, et al.
BMC Medicine|May 28, 2025
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trialXue-Feng Kan, Bin Liang, Xiao-Lin Zhang, et al.
Journal of Cell Science|May 16, 2018
Histone H3K27 methylation modulates the dynamics of FANCD2 on chromatin to facilitate NHEJ and genome stabilityYe Zhang, Jian-Feng Chang, Jin Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2017
Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemiaBing Chen, Lu Jiang, Meng-Ling Zhong, et al.
European Radiology Experimental|June 16, 2026
TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysisRong Ding, Xiao-Yang Xu, Rui-Bao Liu, et al.
Cell Biology and Toxicology|July 1, 2026
HP1γ promotes the progression of colorectal cancer through interaction with RBPJ of the Notch signaling pathwayRui-Bao Zhu, Yi-Jia Xie, Yu-Ting Han, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Pageof 31